Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.

ABSTRACT:

Background

The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma.

Methods

We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles from 185 patients with advanced lung adenocarcinoma. The concordance was defined according to 3 criteria. Class 1 included all targetable driver mutations in 8 genes; class 2 included class 1 mutations plus mutations in KRAS, STK11, and TP53; class 3 included class 2 mutations plus tumor mutation burden (TMB) status.

Results

Collectively, 150 out of 185 patients had mutations in both tissue and plasma samples, while one patient was mutation-negative for b

SUBMITTER: Jiao XD 

PROVIDER: S-EPMC8350084 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature